# EA1131 (NCT02445391)

> Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02445391
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ECOG-ACRIN Cancer Research Group
- Conditions: Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma
- Interventions: Capecitabine; Carboplatin; Cisplatin
- Enrollment: 415
- Primary outcome: 3-year Invasive Disease-Free Survival (IDFS) Rate in Basal-Subtype Patients

## Indexed commentary on EA1131 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5
- YouTube: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ea1131-nct02445391

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02445391", "email": "<work email>"}; the inbox owner confirms by the emailed link.